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Dietetic’s Department, Nottingham, United Kingdom; 2Nottingham University
Hospitals, Queen’s Campus, Paediatrics, Nottingham, United Kingdom
Introduction: There are no real-time online chat rooms established for peer support
and education on tube feeding at Nottingham Adult Cystic Fibrosis (CF) Unit, even
though traditional focus groups are not possible because of the strict protocol on
patient segregation.
Aim: To evaluate Webex. conferencing for hosting ‘online chat rooms’.
Method: A retrospective questionnaire was completed by e-mail or face to face
with 23 home tube feeding patients (mean age 29) and the CF Dietitian, as part of
the qualitative real-time study on exploring patient experiences of tube feeding.
Results: 15 patients were evaluated; 100% wanted to re-use the chat room;
93% stated it was the ﬁrst time they ‘chatted’ online with others about tube feeding;
93% preferred the Dietitian facilitating, with 80% not wanting to lead future chat
rooms; webcams (13%) and telephone (7%) were stated as additional functions for
improvement and 3−5 patients was the optimal range per chat room.
Pros: “The chat room was easy to use and lead to a pretty uninhibited exchange
of views. I can’t think of a better way for a group of people with CF to discuss
issues . . . ” “. . . it gave me a chance to talk to people in the same situation as
myself, you don’t feel so alone knowing someone else is going through the same
problems etc.” and “enjoyed it, good to hear others’ opinions. Helped me approach
tube feeding with my girlfriend.”
Cons: “Being slow at typing held up the conversation” and “When several people
were typing comments at the same time made it hard to keep things in sync.”
Conclusion: Synchronous OFGs can be dynamic, fun, enjoyable and offer invalu-
able peer support amongst patients who are faced with CF social isolation.
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Background: Optimising nutritional status can be difﬁcult for people with Cystic
Fibrosis (CF). The antipsychotic olanzapine is associated with weight gain, leading
to its use in promoting weight gain in patients with anorexia nervosa. This case
series describes the use of olanzapine as an appetite stimulant in CF patients.
Methods: In an adult CF unit, patients who had poor nutritional status despite
intensive management by a multidisciplinary specialist CF team were prescribed
olanzapine 2.5−5mg daily. Clinical measurements, including weight, height and
body mass index (BMI), were recorded during the course of olanzapine therapy.
Adverse events were recorded.
Results: Thirty one patients were treated with 39 courses of olanzapine. Median
age was 22 years (16−43 yr), 17 female. Median BMI at initiation was 16.9 kg/m2
(range 14.8−20.8). Twelve patients took enteral feeds and all patients took oral sip
feeds during treatment.
The median duration of treatment was 10 months (range 2−56). Nineteen pa-
tients completed at least 12 months treatment with olanzapine. After 12 months
treatment, the mean±SD change in BMI was an increase of 1.8±1.5 kg/m2
(p = 0.001, n = 19) and the mean±SD change in weight was an increase of
5.1±4.7 kg (p = 0.038, n = 19). Fifteen patients discontinued treatment within the
ﬁrst 12 months, 7 of whom failed to gain weight. Side effects included drowsiness,
elevation of liver function tests, loss of taste, and restless legs.
Conclusions: Olanzapine can be useful in promoting weight gain in underweight
CF patients in addition to standard methods of optimising nutrition.
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Poor absorption of fat soluble vitamins is common in patients with Cystic Fibrosis
(CF) and pancreatic insufﬁciency. The aim of this study was to evaluate the impact
of introducing a new CF multivitamin preparation, AquADEK (Yasoo Health),
on levels of vitamins A, D, E and K in adults with CF previously prescribed
ADEK (Axcan Pharma). The vitamin content of 2 ADEK vs 2 AquADEK are
as follows: Vitamin A − 18,000iu vs 36,334iu; Vitamin D3 − 800iu vs 1600iu;
Vitamin E − 300iu vs 300iu and Vitamin K − 300mcg vs 1400mcg. A retro-
spective notes review was performed to compare levels of vitamins A, E and
D, parathyroid hormone (PTH) and prothrombin time (PT; surrogate marker of
vitamin K levels) before and after introducing AquADEK. Measurements were
made at annual review (which occurred at the same time of year). Paired data
were available for 64 patients (total clinic n = 249), mean(SD) age 27.1(0.8) years,
FEV1 63.6(22.1)%, BMI 22.2(2.7) kg/m2. The time between ﬁrst prescription
of AquADEK and vitamin level measurement was 263(112) days. Mean(SD)
concentrations of analytes before and after changing to AquADEK [normal range in
square brackets] were: vitamin A: 1.54(0.60) vs 1.63(0.57)mmol/l, p = 0.20 [1.05–
2.80mmol/l]; 25-hydroxyvitamin D: 16.96(7.84) vs 21.51(10.22) ng/ml, p = 0.0001
[>20 ng/ml]; PTH: 52.98(31.32) vs 43.00(21.53) ng/l, p = 0.03 [14−72 ng/l]; vi-
tamin E: 25.86(11.20) vs 22.79(8.7)mmol/l, p = 0.019 [11.5–35.0mmol/l]; PT:
12.5(1.22) vs 12.73(1.03) s, p = 0.087 [10.1–15.3 s].
In conclusion, the introduction of AquADEK has led to a signiﬁcant improvement
in vitamin D levels but a reduction in vitamin E levels in CF adults attending our
centre.
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Introduction: Pancreatic insufﬁciency (PI) in cystic ﬁbrosis (CF) is the main cause
of impaired digestion and absorption, foremost fats and proteins, and fat-soluble
vitamins as a consequence.
Aim: Investigate the status of fat-soluble vitamins (A and E) in children with CF,
and efﬁciency of these vitamins standard oral supplementation.
Materials and Methods: First group − 11 new-born PI CF patients, revealed
as a result of neonatal screening program in Moscow. Concentrations of serum
vitamins A and E were investigated at the time of diagnosis, then after one
month of being on pancreatic enzymes (Creon) only and after another month of
combined enzymes and vitamins treatment (vitamin A − 3000ME and E − 25ME
per day). Second group − 14 CF children from Moscow (age 7−11 yrs), regularly
receiving fat-soluble vitamins in standard doses (vitamins of A − 3000ME and
E − 200ME per day). Serum levels of retinol and tocopherol were determined by
high-performance liquid chromatography.
Results: In the ﬁst group a concentration (M±m) of vitamins A and E in blood
was 12.3±2.2mkg/dl and 0.52±0.12mg/dl accordingly. Level of retinol on enzyme
therapy raised on 36.3% (p< 0.051) and after adding vitamin A increased on
84.1% (p< 0.03). Levels of serum tocopherol did not change signiﬁcantly despite of
adding pancreatic enzymes and then vitamin E. In half of children from the second
group we revealed insufﬁciency of vitamin A. Deﬁcit of vitamin E was even more
marked − up to 86% of patients had low concentration of vitamin E.
Conclusion: Doses of vitamins A and E, recommended by the European consensus
(Sinaasappel M, et al. Journal of Cystic Fibrosis 2002; 1: 67−91) don’t normalize
vitamin status of Moscow CF patients.
